1. Home
  2. HURA vs BZFD Comparison

HURA vs BZFD Comparison

Compare HURA & BZFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • BZFD
  • Stock Information
  • Founded
  • HURA 2009
  • BZFD 2006
  • Country
  • HURA United States
  • BZFD United States
  • Employees
  • HURA N/A
  • BZFD N/A
  • Industry
  • HURA
  • BZFD Movies/Entertainment
  • Sector
  • HURA
  • BZFD Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • BZFD Nasdaq
  • Market Cap
  • HURA 96.5M
  • BZFD 77.5M
  • IPO Year
  • HURA N/A
  • BZFD N/A
  • Fundamental
  • Price
  • HURA $3.48
  • BZFD $2.16
  • Analyst Decision
  • HURA Strong Buy
  • BZFD
  • Analyst Count
  • HURA 2
  • BZFD 0
  • Target Price
  • HURA $12.00
  • BZFD N/A
  • AVG Volume (30 Days)
  • HURA 272.1K
  • BZFD 449.7K
  • Earning Date
  • HURA 05-15-2025
  • BZFD 03-13-2025
  • Dividend Yield
  • HURA N/A
  • BZFD N/A
  • EPS Growth
  • HURA N/A
  • BZFD N/A
  • EPS
  • HURA N/A
  • BZFD N/A
  • Revenue
  • HURA N/A
  • BZFD $189,887,000.00
  • Revenue This Year
  • HURA N/A
  • BZFD $89.62
  • Revenue Next Year
  • HURA $221.29
  • BZFD $4.50
  • P/E Ratio
  • HURA N/A
  • BZFD N/A
  • Revenue Growth
  • HURA N/A
  • BZFD N/A
  • 52 Week Low
  • HURA $1.80
  • BZFD $1.26
  • 52 Week High
  • HURA $14.60
  • BZFD $5.68
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • BZFD 47.56
  • Support Level
  • HURA N/A
  • BZFD $2.04
  • Resistance Level
  • HURA N/A
  • BZFD $2.23
  • Average True Range (ATR)
  • HURA 0.00
  • BZFD 0.15
  • MACD
  • HURA 0.00
  • BZFD 0.02
  • Stochastic Oscillator
  • HURA 0.00
  • BZFD 27.11

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About BZFD BuzzFeed Inc.

BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.

Share on Social Networks: